ASX:MDC Medlab Clinical (MDC) Stock Price, News & Analysis → Gold Mania (From Stansberry Research) (Ad) Free MDC Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume36,677 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Medlab Clinical alerts: Email Address Ad Paradigm PressNever use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...Watch my unredacted video about what I think is coming next right here About Medlab Clinical Stock (ASX:MDC)Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia. Its drug candidate includes NanaBis, a buccal spray from cannabis oil extract for oncology and pain management; and NanoCBD, a buccal spray from hemp oil extract for mental health. The company also develops NanoCelle, a patented sub-micron drug delivery platform that allows passive diffusion of active pharmaceutical ingredients directly into the bloodstream through oral-buccal, sublingual, intranasal, and transdermal or topical delivery. In addition, it offers virtual clinic services. The company was founded in 2012 and is headquartered in Botany, Australia.Read More Ad Paradigm PressNever use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...Watch my unredacted video about what I think is coming next right here MDC Stock News HeadlinesApril 16, 2024 | msn.comMedlab West Africa - the Biggest Medical Lab Event in the Region Returns to LagosMay 20, 2023 | money.usnews.comClinical Laboratory Technician SalaryMay 4, 2024 | Behind the Markets (Ad)Investors Alert: The Next Big Thing in Weight LossUBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Pharma's biggest blockbuster yet." Bank of America predicts it will be the world's first "$100 billion dollar a year drug." And Morgan Stanley predicts 250 million prescriptions will be written each year.February 13, 2023 | msn.comHealthKick Podcast: Aussie Bio Tech Medlab is confident in highly anticipated Phase III trialJanuary 12, 2023 | finance.yahoo.comMEDLAB ANNOUNCES FAVOURABLE INTERIM READOUT OF NANABIS™ REAL-WORLD EVIDENCE (RWE) MEDCARE STUDYDecember 28, 2022 | finance.yahoo.comInsights on the Virtual Clinical Trials Global Market to 2027 - Key Players Include Dassault Systemes, Medable, Science 37 and THREADDecember 27, 2022 | msn.comAustralian biotech Medlab Clinical sets terms for proposed $8M US IPONovember 24, 2022 | finance.yahoo.comMedlab Clinical Full Year 2022 Earnings: Beats ExpectationsMay 4, 2024 | Behind the Markets (Ad)Investors Alert: The Next Big Thing in Weight LossUBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Pharma's biggest blockbuster yet." Bank of America predicts it will be the world's first "$100 billion dollar a year drug." And Morgan Stanley predicts 250 million prescriptions will be written each year.October 13, 2022 | marketwatch.comMedlab Clinical Ltd. Files to List on NasdaqOctober 8, 2022 | finance.yahoo.comNICKLAUS CHILDREN'S HEALTH SYSTEM OFFERS SCHOLARSHIPS FOR STUDENTS IN MIAMI-DADE COLLEGE'S ASSOCIATE OF SCIENCE IN NURSING PROGRAMOctober 3, 2022 | reuters.comMedlab Clinical LtdSeptember 23, 2022 | finance.yahoo.comM.D.C. Holdings, Inc. (MDC)September 10, 2022 | usnews.comMiami Dade College User ReviewsAugust 25, 2022 | forbes.comSurviving Inflation, Labor And Supply Chain ChallengesAugust 1, 2022 | finance.yahoo.comWhat You Need To Know About Medlab Clinical Limited's (ASX:MDC) Investor CompositionMay 21, 2022 | msn.comWeed Week: Woody Harrelson opens weed dispensary and Byron Bay could be home to a cannabis resortFebruary 26, 2022 | msn.comWeed Week: New York hemp farmers get green light for cannabis cropsJanuary 15, 2022 | msn.comWeed Week: Cannabis compounds could prevent Covid and Quebec’s no-jab, no-weed rule quadruples vaccinationsJanuary 14, 2022 | finance.yahoo.comMedlab (ASX:MDC) receives Government grant to apply NanoCelle® to an RNA nasal vaccine in collaboration with University of NSW (UNSW) and Macquarie University (MQ) to fight COVID-19 future potential epidemicsNovember 4, 2021 | finance.yahoo.comNanocelle® Patent Granted in UsaOctober 11, 2021 | finance.yahoo.comDEPRESSION PATENT FOR OROTATE APPROVED & GRANTED BY US PATENT OFFICEOctober 6, 2021 | finance.yahoo.comNANOCELLE “ISSUE OF ALLOWANCE” BY US PATENT OFFICESeptember 4, 2021 | investing.comMedlab Clinical Ltd (MDC)September 2, 2021 | finance.yahoo.comHere's Why We're Not Too Worried About Medlab Clinical's (ASX:MDC) Cash Burn SituationAugust 31, 2021 | sg.finance.yahoo.comMedlab Clinical Limited (MDC.AX)July 27, 2021 | finance.yahoo.comUS Patent Office issues Notice of Allowance status for NRGBiotic™ for treating, preventing, or Ameliorating depression or a Depressive disorder.See More Headlines Receive MDC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medlab Clinical and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:MDC CUSIPN/A CIKN/A Webwww.medlab.co Phone61 2 8188 0311FaxN/AEmployees1,773Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($547.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,920,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-121.86% Return on Assets-75.51% Debt Debt-to-Equity Ratio28.56 Current Ratio1.58 Quick Ratio3.71 Sales & Book Value Annual Sales$1.66 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow5.12 Book ValueA$1.42 per share Price / BookN/AMiscellaneous Outstanding Shares2,280,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.90 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Sean Michael Hall (Age 54)MD, CEO & Director Comp: $574.11kMr. Kerem Kaya (Age 51)CFO, COO & Company Secretary Comp: $292.83kDr. David A. Rutolo (USA)J.D., Ph.D., Director of ScienceMr. Ian CurtinsmithChief Information OfficerKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All Competitors MDC Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Medlab Clinical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medlab Clinical investors own include iSignthis (ISX), FBR (FBR), Embark Early Education (EVO), Dacian Gold (DCN), Constellation Technologies (CT1), Bod Australia (BDA), Afterpay (APT), Alkane Resources (ALK) and AusCann Group (AC8). This page (ASX:MDC) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldInvestors Alert: The Next Big Thing in Weight LossBehind the MarketsStock-Picking AI Predicts #1 Stock of 2024AltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithGlobal crypto currency reset (41 major banks signed up)Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medlab Clinical Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
